Emcure Pharmaceuticals Management Guidance Tracker
12 forward-looking guidance items tracked across 3 quarters.
Margins
Management guided for 100 bps improvement in opex and 50 bps gross margin expansion, driven by productivity gains and product mix.
Q1 FY265-year EBITDA margin target of 23-24%TrackedOver the next 4-5 years, EBITDA margins are expected to improve by 300-400 bps from current ~20% levels.
Q3 FY26EBITDA margin expansion of 300-400 bps over 3-5 yearsTrackedManagement expects ~100 bps annual EBITDA margin improvement, targeting 23-24% over 3-4 years organically.
Q4 FY26EBITDA margin expansion: 75-100 bpsTrackedManagement committed to expanding EBITDA margins by 75-100 basis points in FY27, driven by operating leverage and productivity gains.
Capex
Capex spending guided at ~₹350 crore per annum, with ~₹150 crore for maintenance and ~₹200 crore for capacity/product-specific investments.
Q3 FY26Capex of ₹350-400 crore per year for next 2-3 yearsTrackedAnnual capital expenditure is expected to remain in the range of ₹350-400 crore, excluding acquisitions.
Q4 FY26Capex guidance: ₹400-425 crore for FY27TrackedCapital expenditure for FY27 is expected to be in the range of ₹400-425 crore.
Revenue
The acquired oral diabetes portfolio from Sanofi (brands Emeril and Pain) is expected to contribute ~₹200 crore on an annualized basis, with ~8 months of revenue in FY26.
Q3 FY26Revenue growth of low-to-mid teens CAGR over 3-5 yearsTrackedManagement aspires for a low-to-mid teens compounded revenue growth rate, driven by domestic outperformance and international expansion.
Q4 FY26FY27 revenue growth: low-to-mid teensTrackedManagement expects revenue growth in the low-to-mid teen percentage range for FY27, assuming stable macro conditions.